{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:23:41Z","timestamp":1792020221481,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H06229"],"award-info":[{"award-number":["18H06229"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007591","name":"Akiyama Life Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007591","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s11102-023-01350-3","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T11:03:18Z","timestamp":1693306998000},"page":"597-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas"],"prefix":"10.1007","volume":"26","author":[{"given":"Tomonori","family":"Sekizaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-6688","authenticated-orcid":false,"given":"Hiraku","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Yong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitomo","family":"Ishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Motegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"issue":"9522","key":"1350_CR1","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing\u2019s syndrome. Lancet 367(9522):1605\u20131617. https:\/\/doi.org\/10.1016\/S0140-6736(06)68699-6","journal-title":"Lancet"},{"issue":"6","key":"1350_CR2","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1210\/jc.2012-3582","volume":"98","author":"OM Dekkers","year":"2013","unstructured":"Dekkers OM, Horv\u00e1th-Puh\u00f3 E, J\u00f8rgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP et al (2013) Multisystem morbidity and mortality in Cushing\u2019s syndrome: a cohort study. J Clin Endocrinol Metab 98(6):2277\u20132284. https:\/\/doi.org\/10.1210\/jc.2012-3582","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1350_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1530\/EJE-19-0464","volume":"181","author":"E Valassi","year":"2019","unstructured":"Valassi E, Tabarin A, Brue T, Feelders RA, Reincke M, Netea-Maier R et al (2019) High mortality within 90 days of diagnosis in patients with Cushing\u2019s syndrome: results from the ERCUSYN registry. Eur J Endocrinol 181(5):461\u2013472. https:\/\/doi.org\/10.1530\/EJE-19-0464","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1350_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1350_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing\u2019s disease. Endocr Rev 36(4):385\u2013486. https:\/\/doi.org\/10.1210\/er.2013-1048","journal-title":"Endocr Rev"},{"issue":"1","key":"1350_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M et al (2009) Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94(1):115\u2013122. https:\/\/doi.org\/10.1210\/jc.2008-1008","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1350_CR7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M et al (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366(10):914\u2013924. https:\/\/doi.org\/10.1056\/NEJMoa1105743","journal-title":"N Engl J Med"},{"issue":"1","key":"1350_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","volume":"6","author":"A Lacroix","year":"2018","unstructured":"Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P et al (2018) Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 6(1):17\u201326. https:\/\/doi.org\/10.1016\/S2213-8587(17)30326-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1350_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11102-019-00984-6","volume":"22","author":"L Manetti","year":"2019","unstructured":"Manetti L, Deutschbein T, Schopohl J, Yuen KCJ, Roughton M, Kriemler-Krahn U et al (2019) Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing\u2019s disease: interim results from a long-term real-world evidence study. Pituitary 22(5):542\u2013551. https:\/\/doi.org\/10.1007\/s11102-019-00984-6","journal-title":"Pituitary"},{"key":"1350_CR10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3389\/fendo.2020.00648","volume":"11","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, De Leo M, Cozzolino A, Colao A (2020) Medical treatment of Cushing\u2019s disease: an overview of the current and recent clinical trials. Front Endocrinol (Lausanne) 11:648. https:\/\/doi.org\/10.3389\/fendo.2020.00648","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"1350_CR11","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1210\/clinem\/dgab122","volume":"106","author":"F Castinetti","year":"2021","unstructured":"Castinetti F, Nieman LK, Reincke M, Newell-Price J (2021) Approach to the patient treated with steroidogenesis inhibitors. J Clin Endocrinol Metab 106(7):2114\u20132123. https:\/\/doi.org\/10.1210\/clinem\/dgab122","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1350_CR12","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1172\/JCI60417","volume":"121","author":"H Fukuoka","year":"2011","unstructured":"Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D et al (2011) EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 121(12):4712\u20134721. https:\/\/doi.org\/10.1172\/JCI60417","journal-title":"J Clin Invest"},{"issue":"20","key":"1350_CR13","doi-asserted-by":"publisher","first-page":"8414","DOI":"10.1073\/pnas.1018091108","volume":"108","author":"NA Liu","year":"2011","unstructured":"Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S et al (2011) Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci U S A 108(20):8414\u20138419. https:\/\/doi.org\/10.1073\/pnas.1018091108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1350_CR14","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1210\/jc.2015-1606","volume":"100","author":"NA Liu","year":"2015","unstructured":"Liu NA, Araki T, Cuevas-Ramos D, Hong J, Ben-Shlomo A, Tone Y et al (2015) Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing disease. J Clin Endocrinol Metab 100(7):2557\u20132564. https:\/\/doi.org\/10.1210\/jc.2015-1606","journal-title":"J Clin Endocrinol Metab"},{"key":"1350_CR15","doi-asserted-by":"publisher","unstructured":"Shen Y, Ji C, Jian X, Zhou J, Zhang Q, Qiao N et al (2021) Regulation of the EGFR Pathway by HSP90 Is Involved in the Pathogenesis of Cushing\u2019s Disease. Front Endocrinol (Lausanne) 11601984. https:\/\/doi.org\/10.3389\/fendo.2020.601984","DOI":"10.3389\/fendo.2020.601984"},{"issue":"2","key":"1350_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1507\/endocrj.EJ19-0239","volume":"67","author":"K Kageyama","year":"2020","unstructured":"Kageyama K, Asari Y, Sugimoto Y, Niioka K, Daimon M (2020) Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation. Endocr J 67(2):177\u2013184. https:\/\/doi.org\/10.1507\/endocrj.EJ19-0239","journal-title":"Endocr J"},{"issue":"8","key":"1350_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1530\/ERC-21-0093","volume":"28","author":"D Treppiedi","year":"2021","unstructured":"Treppiedi D, Di Muro G, Marra G, Barbieri AM, Mangili F, Catalano R et al (2021) USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs. Endocr Relat Cancer 28(8):573\u2013582. https:\/\/doi.org\/10.1530\/ERC-21-0093","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"1350_CR18","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1210\/jc.2017-00464","volume":"102","author":"J Lu","year":"2017","unstructured":"Lu J, Chatain GP, Bugarini A, Wang X, Maric D, Walbridge S et al (2017) Histone deacetylase inhibitor SAHA is a promising treatment of cushing disease. J Clin Endocrinol Metab 102(8):2825\u20132835. https:\/\/doi.org\/10.1210\/jc.2017-00464","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1350_CR19","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1210\/clinem\/dgaa699","volume":"106","author":"D Zhang","year":"2021","unstructured":"Zhang D, Damoiseaux R, Babayan L, Rivera-Meza EK, Yang Y, Bergsneider M et al (2021) Targeting corticotroph HDAC and PI3-Kinase in Cushing disease. J Clin Endocrinol Metab 106(1):e232\u2013e246. https:\/\/doi.org\/10.1210\/clinem\/dgaa699","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1350_CR20","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1210\/clinem\/dgaa699","volume":"106","author":"Z Chen","year":"2021","unstructured":"Chen Z, Jia Q, Zhao Z, Zhang Q, Chen Y, Qiao N et al (2021) Transcription factor ASCL1 acts as a novel potential therapeutic target for the treatment of the Cushing\u2019s disease. J Clin Endocrinol Metab 106(1):e232\u2013e246. https:\/\/doi.org\/10.1210\/clinem\/dgaa699","journal-title":"J Clin Endocrinol Metab"},{"key":"1350_CR21","doi-asserted-by":"publisher","unstructured":"Ohki-Hamazaki H, Neuromedin B, Prog Neurobiol (2000) 62(3):297\u2013312. https:\/\/doi.org\/10.1016\/s0301-0082(00)00004-6","DOI":"10.1016\/s0301-0082(00)00004-6"},{"issue":"1","key":"1350_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2170\/jjphysiol.45.37","volume":"45","author":"S Itoh","year":"1995","unstructured":"Itoh S, Takashima A, Itoh T, Morimoto T (1995) Effects of neuromedins and related peptides on the body temperature of rats. Jpn J Physiol 45(1):37\u201345. https:\/\/doi.org\/10.2170\/jjphysiol.45.37","journal-title":"Jpn J Physiol"},{"issue":"1","key":"1350_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/0006-291x(84)91611-5","volume":"119","author":"N Minamino","year":"1984","unstructured":"Minamino N, Kangawa K, Matsuo H, Neuromedin C (1984) A bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun 119(1):14\u201320. https:\/\/doi.org\/10.1016\/0006-291x(84)91611-5","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1350_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3181\/00379727-183-42398","volume":"183","author":"GH Greeley Jr","year":"1986","unstructured":"Greeley GH Jr, Spannagel A, Hill FL, Thompson JC (1986) Comparison of the actions of bombesin, gastrin-releasing peptide-27, neuromedin B, and gastrin-releasing peptide-10 in causing release of gastrin and gastric inhibitory peptide in rats. Proc Soc Exp Biol Med 183(1):136\u2013139. https:\/\/doi.org\/10.3181\/00379727-183-42398","journal-title":"Proc Soc Exp Biol Med"},{"issue":"2","key":"1350_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000199318","volume":"34","author":"M Namba","year":"1986","unstructured":"Namba M, Ghatei MA, Ghiglione M, Bloom SR (1986) Effects of decapeptide of mammalian bombesin and neuromedin B on pancreatic exocrine secretion in the rat. Digestion 34(2):105\u2013114. https:\/\/doi.org\/10.1007\/0.1159\/000199318","journal-title":"Digestion"},{"issue":"4 Pt 1","key":"1350_CR26","doi-asserted-by":"publisher","first-page":"G491","DOI":"10.1152\/ajpgi.1987.252.4.G491","volume":"252","author":"M Otsuki","year":"1987","unstructured":"Otsuki M, Fujii M, Nakamura T, Tani S, Oka T, Yajima H et al (1987) Effects of neuromedin B and neuromedin C on exocrine and endocrine rat pancreas. Am J Physiol 252(4 Pt 1):G491\u2013498. https:\/\/doi.org\/10.1152\/ajpgi.1987.252.4.G491","journal-title":"Am J Physiol"},{"issue":"Suppl 3","key":"1350_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0196-9781(85)90383-3","volume":"6","author":"M Namba","year":"1985","unstructured":"Namba M, Ghatei MA, Bishop AE, Gibson SJ, Mann DJ, Polak JM et al (1985) Presence of neuromedin B-like immunoreactivity in the brain and gut of rat and guinea-pig. Peptides 6(Suppl 3):257\u2013263. https:\/\/doi.org\/10.1016\/0196-9781(85)90383-3","journal-title":"Peptides"},{"issue":"1","key":"1350_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1677\/jme.1.01892","volume":"36","author":"KJ Oliveira","year":"2006","unstructured":"Oliveira KJ, Ortiga-Carvalho TM, Cabanelas A, Veiga MA, Aoki K, Ohki-Hamazaki H et al (2006) Disruption of neuromedin B receptor gene results in dysregulation of the pituitary-thyroid axis. J Mol Endocrinol 36(1):73\u201380. https:\/\/doi.org\/10.1677\/jme.1.01892","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"1350_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0940-2993(11)80279-4","volume":"47","author":"LK Malendowicz","year":"1995","unstructured":"Malendowicz LK, Nussdorfer GG (1995) Investigations on the acute effects of neuropeptides on the pituitary-adrenocortical function in normal and cold-stressed rats. I. Bombesin and neuromedin B. Exp Toxicol Pathol 47(1):31\u201334. https:\/\/doi.org\/10.1016\/S0940-2993(11)80279-4","journal-title":"Exp Toxicol Pathol"},{"issue":"7","key":"1350_CR30","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1210\/en.2013-2077","volume":"155","author":"H Kameda","year":"2014","unstructured":"Kameda H, Miyoshi H, Shimizu C, Nagai S, Nakamura A, Kondo T et al (2014) Expression and regulation of neuromedin B in pituitary corticotrophs of male melanocortin 2 receptor-deficient mice. Endocrinology 155(7):2492\u20132499. https:\/\/doi.org\/10.1210\/en.2013-2077","journal-title":"Endocrinology"},{"issue":"2","key":"1350_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1507\/endocrj.ej12-0299","volume":"60","author":"K Kageyama","year":"2013","unstructured":"Kageyama K, Oki Y, Sakihara S, Nigawara T, Terui K, Suda T (2013) Evaluation of the diagnostic criteria for Cushing\u2019s disease in Japan. Endocr J 60(2):127\u2013135. https:\/\/doi.org\/10.1507\/endocrj.ej12-0299","journal-title":"Endocr J"},{"issue":"1","key":"1350_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2011.08.014","volume":"312","author":"HJ Park","year":"2011","unstructured":"Park HJ, Kim SR, Kim MK, Choi KS, Jang HO, Yun I et al (2011) Neuromedin B receptor antagonist suppresses tumor angiogenesis and tumor growth in vitro and in vivo. Cancer Lett 312(1):117\u2013127. https:\/\/doi.org\/10.1016\/j.canlet.2011.08.014","journal-title":"Cancer Lett"},{"issue":"2","key":"1350_CR33","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/0006-291x(83)90814-8","volume":"114","author":"N Minamino","year":"1983","unstructured":"Minamino N, Kangawa K, Matsuo H (1983) Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun 114(2):541\u2013548. https:\/\/doi.org\/10.1016\/0006-291x(83)90814-8","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1350_CR34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1006\/pupt.1999.0210","volume":"12","author":"JM Siegfried","year":"1999","unstructured":"Siegfried JM, Krishnamachary N, Gaither Davis A, Gubish C, Hunt JD, Shriver SP (1999) Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Pulm Pharmacol Ther 12(5):291\u2013302. https:\/\/doi.org\/10.1006\/pupt.1999.0210","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"1350_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/(sici)1097-0045(20000301)42:4<295::aid-pros7>3.0.co;2-b","volume":"42","author":"B Sun","year":"2000","unstructured":"Sun B, Halmos G, Schally AV, Wang X, Martinez M (2000) Presence of receptors for bombesin\/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 42(4):295\u2013303. https:\/\/doi.org\/10.1002\/(sici)1097-0045(20000301)42:4<295::aid-pros7>3.0.co;2-b","journal-title":"Prostate"},{"issue":"4","key":"1350_CR36","doi-asserted-by":"publisher","first-page":"G718","DOI":"10.1152\/ajpgi.00156.2004","volume":"288","author":"D Matusiak","year":"2005","unstructured":"Matusiak D, Glover S, Nathaniel R, Matkowskyj K, Yang J, Benya RV (2005) Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon. Am J Physiol Gastrointest Liver Physiol 288(4):G718\u2013728. https:\/\/doi.org\/10.1152\/ajpgi.00156.2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"1350_CR37","first-page":"1202","volume":"290","author":"RR Ryan","year":"1999","unstructured":"Ryan RR, Katsuno T, Mantey SA, Pradhan TK, Weber HC, Coy DH et al (1999) Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD168368. J Pharmacol Exp Ther 290(3):1202\u20131211","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1350_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/s0014-2999(00)00828-1","volume":"409","author":"TW Moody","year":"2000","unstructured":"Moody TW, Jensen RT, Garcia L, Leyton J (2000) Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells. Eur J Pharmacol 409(2):133\u2013142. https:\/\/doi.org\/10.1016\/s0014-2999(00)00828-1","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1350_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s0014-2999(03)01996-4","volume":"474","author":"TW Moody","year":"2003","unstructured":"Moody TW, Leyton J, Garcia-Marin L, Jensen RT (2003) Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur J Pharmacol 474(1):21\u201329. https:\/\/doi.org\/10.1016\/s0014-2999(03)01996-4","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1350_CR40","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/eje.0.143r001","volume":"143","author":"S Jordan","year":"2000","unstructured":"Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB (2000) Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 143(1):R1\u20136. https:\/\/doi.org\/10.1530\/eje.0.143r001","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"1350_CR41","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1210\/me.2010-0091","volume":"24","author":"A Roussel-Gervais","year":"2010","unstructured":"Roussel-Gervais A, Bilodeau S, Vallette S, Berthelet F, Lacroix A, Figarella-Branger D et al (2010) Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis. Mol Endocrinol 24(9):1835\u20131845. https:\/\/doi.org\/10.1210\/me.2010-0091","journal-title":"Mol Endocrinol"},{"key":"1350_CR42","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3389\/fendo.2018.00444","volume":"9","author":"T Araki","year":"2018","unstructured":"Araki T, Liu NA (2018) Cell cycle regulators and lineage-specific therapeutic targets for Cushing Disease. Front Endocrinol (Lausanne) 9:444. https:\/\/doi.org\/10.3389\/fendo.2018.00444","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1350_CR43","doi-asserted-by":"publisher","unstructured":"Liu NA, Ben-Shlomo A, Carmichael JD, Wang C, Swerdloff RS, Heaney AP et al (2022) Treatment of Cushing\u2019s Disease with Pituitary-Targeting Seliciclib. J Clin Endocrinol Metab dgac588. https:\/\/doi.org\/10.1210\/clinem\/dgac588","DOI":"10.1210\/clinem\/dgac588"},{"issue":"18","key":"1350_CR44","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.ejca.2010.08.001","volume":"46","author":"C Le Tourneau","year":"2010","unstructured":"Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V et al (2010) Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 46(18):3243\u20133250. https:\/\/doi.org\/10.1016\/j.ejca.2010.08.001","journal-title":"Eur J Cancer"},{"issue":"2","key":"1350_CR45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1677\/joe.1.05616","volume":"183","author":"M Theodoropoulou","year":"2004","unstructured":"Theodoropoulou M, Arzberger T, Gruebler Y, Jaffrain-Rea ML, Schlegel J, Schaaf L et al (2004) Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol 183(2):385\u2013394. https:\/\/doi.org\/10.1677\/joe.1.05616","journal-title":"J Endocrinol"},{"issue":"1","key":"1350_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ng.3166","volume":"47","author":"M Reincke","year":"2015","unstructured":"Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F et al (2015) Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat Genet 47(1):31\u201338. https:\/\/doi.org\/10.1038\/ng.3166","journal-title":"Nat Genet"},{"issue":"2","key":"1350_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1210\/js.2016-1053","volume":"1","author":"T Araki","year":"2017","unstructured":"Araki T, Liu X, Kameda H, Tone Y, Fukuoka H, Tone M et al (2017) EGFR induces E2F1-Mediated Corticotroph Tumorigenesis. J Endocr Soc 1(2):127\u2013143. https:\/\/doi.org\/10.1210\/js.2016-1053","journal-title":"J Endocr Soc"},{"issue":"23","key":"1350_CR48","doi-asserted-by":"publisher","first-page":"9132","DOI":"10.3390\/ijms21239132","volume":"21","author":"H Fukuoka","year":"2020","unstructured":"Fukuoka H, Shichi H, Yamamoto M, Takahashi Y (2020) The Mechanisms Underlying Autonomous adrenocorticotropic hormone secretion in Cushing\u2019s Disease. Int J Mol Sci 21(23):9132. https:\/\/doi.org\/10.3390\/ijms21239132","journal-title":"Int J Mol Sci"},{"issue":"1\u20133","key":"1350_CR49","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejphar.2010.03.057","volume":"637","author":"TW Moody","year":"2010","unstructured":"Moody TW, Berna MJ, Mantey S, Sancho V, Ridnour L, Wink DA et al (2010) Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. Eur J Pharmacol 637(1\u20133):38\u201345. https:\/\/doi.org\/10.1016\/j.ejphar.2010.03.057","journal-title":"Eur J Pharmacol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01350-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01350-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01350-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T03:12:58Z","timestamp":1695870778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01350-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1350"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01350-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3122899\/v1","asserted-by":"object"}]},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"21 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board (No. 018\u20130201). All patients agreed to participate in the study and provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}